Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

29.91 -0.47 (-1.55%)
Streaming Delayed Price Updated: 12:18 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom ↗
Via Chartmill
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends ↗
NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what... 
Via MarketBeat
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials. 
Via The Motley Fool
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Bain Capital sold its entire stake in Nuvalent stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.